Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pieris Pharmaceuticals Inc
(NQ:
PIRS
)
10.97
-0.28 (-2.49%)
Streaming Delayed Price
Updated: 3:57 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pieris Pharmaceuticals Inc
< Previous
1
2
Next >
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
February 23, 2022
BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
January 14, 2022
BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
January 03, 2022
BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
November 11, 2021
BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
November 08, 2021
BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 02, 2021
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT - Dosing completed in part 1a of phase 2a study of PRS-060/AZD1402 - Dosing to begin this quarter in phase 2...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
October 26, 2021
BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
October 06, 2021
BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
September 09, 2021
BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
August 24, 2021
BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT - Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Exposures
Product Safety
Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team
August 03, 2021
- Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer - Shane Olwill, Ph.D., promoted to Chief Development Officer BOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc....
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021
July 28, 2021
BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
June 25, 2021
- PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis -...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Topics
Death
Exposures
COVID-19
Death
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
June 24, 2021
BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Exposures
Product Safety
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
May 25, 2021
- Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs -...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
May 20, 2021
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT - PRS-060/AZD1402 dosed to first patient in phase 2a study - Cinrebafusp alfa (PRS-343) phase 2 study expected to...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
May 10, 2021
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
April 26, 2021
- Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties - Boston Pharmaceuticals will be primarily responsible for development of the...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
April 10, 2021
- Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa - Durable anti-tumor activity...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.